Ueber Immunisierungsversuche mit den Friedmannschen Schildkrötentuberkelbazillen an Meerschweinchen und Kaninchen

Uhlenhuth, P.; Lange, Ludwig

doi:10.1055/s-0029-1193070

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moeller had derived his mycobacteria from blindworms and Friedmann from turtles (Friedmann, 1903(Friedmann, , 1904Moeller, 1903Moeller, , 1904Calmette et al, 1927). Intriguingly, these mycobacteria could be cultured at 25 • C, but did not replicate at 37 • C. Both vaccines were commercialized, but it was soon established that experimental animals immunized with these live vaccines did not survive challenge with M. tuberculosis (Uhlenhuth and Lange, 1920). These approaches followed Jenner's strategy, who in 1796 had published his successful vaccination against smallpox using cowpox (Jenner, 1798).…”

Section: Different Approaches Toward Development Of a Tuberculosis Vaccinementioning

confidence: 99%

Vaccine Development Against Tuberculosis Over the Last 140 Years: Failure as Part of Success

Kaufmann

2021

Front. Microbiol.

View full text Add to dashboard Cite

The year 2020 was shaped by the COVID-19 pandemic which killed more people than any other infectious disease in this particular year. At the same time, the development of highly efficacious COVID-19 vaccines within less than a year raises hope that this threat can be tamed in the near future. For the last 200 years, the agent of tuberculosis (TB) has been the worst killer amongst all pathogens. Although a vaccine has been available for 100 years, TB remains a substantial threat. The TB vaccine, Bacille Calmette-Guérin (BCG), has saved tens of millions of lives since its deployment. It was the best and only choice available amongst many attempts to develop efficacious vaccines and all competitors, be they subunit vaccines, viable vaccines or killed whole cell vaccines have failed. Yet, BCG is insufficient. The last decades have witnessed a reawakening of novel vaccine approaches based on deeper insights into immunity underlying TB and BCG immunization. In addition, technical advances in molecular genetics and the design of viral vectors and adjuvants have facilitated TB vaccine development. This treatise discusses firstly early TB vaccine developments leading to BCG as the sole preventive measure which stood the test of time, but failed to significantly contribute to TB control and secondly more recent attempts to develop novel vaccines are described that focus on the genetically modified BCG-based vaccine VPM1002, which has become the frontrunner amongst viable TB vaccine candidates. It is hoped that highly efficacious vaccines against TB will become available even though it remains unclear whether and when this ambition can be accomplished. None the less it is clear that the goal of reducing TB morbidity and mortality by 90% or 95%, respectively, by 2030 as proposed by the World Health Organization depends significantly on better vaccines.

show abstract

Section: Different Approaches Toward Development Of a Tuberculosis Vaccinementioning

confidence: 99%